BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sym004: Phase I/II started

Symphogen began an open-label, dose-escalation, international Phase I/II trial to evaluate 0.4 to 12 mg/kg IV Sym004 given once weekly in patients. The Phase I portion will evaluate Sym004 in 42...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >